Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEYAZ vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins (FSH and LH) from the pituitary, inhibiting ovulation, altering cervical mucus, and inducing endometrial changes. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Contraception,Treatment of premenstrual dysphoric disorder (PMDD),Treatment of moderate acne vulgaris in women at least 14 years old who have achieved menarche and desire contraception
Prevention of pregnancy (FDA-approved)
One tablet (drospirenone 3 mg / ethinyl estradiol 0.02 mg) orally once daily for 24 days, followed by 4 days of placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Drospirenone: approximately 30 hours (terminal). Ethinyl estradiol: approximately 13-15 hours (terminal). Steady-state reached within 10 days. Clinical context: once-daily dosing maintains therapeutic levels with minimal accumulation after 3-4 cycles.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Primarily hepatic via CYP3A4. Ethinyl estradiol undergoes first-pass metabolism in the liver and gut wall. Drospirenone is metabolized via CYP3A4 and also undergoes reduction and sulfation. Metabolites are excreted in urine and feces.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Urine (45-55% as metabolites), feces (30-40% as metabolites), with enterohepatic recirculation of ethinyl estradiol metabolites.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Drospirenone: 95-97% bound (primarily to albumin). Ethinyl estradiol: approximately 98% bound (mostly to albumin).
~99% bound to serum albumin and sex hormone-binding globulin.
Drospirenone: approximately 3.7 L/kg (suggests moderate tissue distribution). Ethinyl estradiol: approximately 3.6 L/kg (consistent with distribution into body water). Clinical meaning: not extensively stored in tissues.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Drospirenone ~76% (relative to IV). Ethinyl estradiol ~55% (due to first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
Contraindicated in patients with renal impairment (creatinine clearance < 50 m L/min). No dose adjustment is recommended for mild impairment (Cr Cl >= 50 m L/min); however, careful monitoring is advised.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C). Do not use in acute or chronic liver disease.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, dose is same as adults: one tablet daily following the 24/4 regimen.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific geriatric dosing is established; use not recommended in this population.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COCs). This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders: venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction,Hepatic disease: jaundice, cholestasis, hepatic adenomas,Hypertension: monitor blood pressure,Hyperkalemia: risk in patients with renal impairment, hepatic impairment, or adrenal insufficiency; avoid use with potassium-sparing diuretics or potassium supplements,Gallbladder disease,Carbohydrate and lipid metabolic effects,Headache/migraine,Bleeding irregularities,Depression,Carcinoma: breast and cervical,Ocular lesions: retinal thrombosis
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer,Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenomas or carcinomas (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Renal impairment,Adrenal insufficiency,Hyperkalemia,Use with potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4, potentially increasing ethinyl estradiol levels and risk of adverse effects. No other specific food interactions are documented, but consider that high potassium foods (e.g., bananas, oranges, spinach) may theoretically contribute to hyperkalemia in susceptible patients, though routine avoidance is not required. Alcohol may increase the risk of liver toxicity, but moderate use is not contraindicated.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy category X. Contraindicated in pregnancy due to known teratogenic effects, including cardiovascular and skeletal anomalies, particularly during first trimester. Use during second and third trimesters is associated with feminization of male fetuses and potential hepatic adenoma. Discontinue immediately if pregnancy occurs.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in human breast milk. M/P ratio not determined. Can reduce milk production and composition. Use is generally contraindicated during breastfeeding due to potential adverse effects in the infant, including jaundice and fluid retention.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable: contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased clearance) are irrelevant as drug should be discontinued.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
BEYAZ (drospirenone/ethinyl estradiol) is a combined oral contraceptive (COC) with a 24/4 regimen. The drospirenone component has antimineralocorticoid activity, which can be beneficial for patients with fluid retention or acne. Monitor potassium levels in patients on concomitant medications that increase potassium (e.g., ACE inhibitors, ARBs, NSAIDs). BEYAZ is contraindicated in patients with renal impairment (Cr Cl <30 m L/min) due to risk of hyperkalemia. The 24 active pill regimen provides a longer window of ovulation suppression and may reduce breakthrough bleeding compared to 21-day regimens. Use with caution in patients with a history of depression; drospirenone may affect mood.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill at the same time each day, preferably in the evening to minimize nausea.,If you miss a pill, follow the package insert instructions: for one missed pill, take it as soon as remembered; for two or more missed pills, use backup contraception (e.g., condoms) for at least 7 days.,Avoid eating grapefruit or drinking grapefruit juice while taking this medication because it can increase estrogen levels and risk of side effects.,Do not smoke while using BEYAZ, especially if you are over 35, as smoking increases the risk of serious cardiovascular events.,Side effects may include nausea, breast tenderness, headache, and mood changes; report persistent symptoms to your provider.,Seek immediate medical attention if you experience signs of a blood clot: sudden leg swelling, chest pain, shortness of breath, or sudden severe headache.,BEYAZ does not protect against HIV or other sexually transmitted infections; use condoms for protection.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEYAZ vs AFIRMELLE, answered by our medical review team.
BEYAZ is a Oral Contraceptive that works by Combination of ethinyl estradiol and drospirenone suppresses gonadotropins (FSH and LH) from the pituitary, inhibiting ovulation, altering cervical mucus, and inducing endometrial changes. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEYAZ and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEYAZ is: One tablet (drospirenone 3 mg / ethinyl estradiol 0.02 mg) orally once daily for 24 days, followed by 4 days of placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEYAZ and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEYAZ is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to known teratogenic effects, including cardiovascular and skeletal anomalies, particularly during first trimester. Use durin. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.